We have partnered with companies that are researching and developing a wide range of cell & gene therapies to combat complex and recurring diseases.
CAR T-Cell therapy
We offer cutting-edge CAR-T Cell therapies to combat both hematological malignancies and solid tumors. Currently, we offer CD19, CD22, CD7, CD5, CD33, CD123 and BCMA vectors for treating leukemia, lymphoma, multiple myeloma, and autoimmune diseases.
We are working on a wide range of tumor antigens to address the need for CAR T Cell therapy in solid tumors.
CRISPR/CAS9 Gene Therapy
CRISPR/Cas9 gene therapy is a revolutionary technology that enables the precise editing of genes by targeting and modifying DNA sequences. This technique utilizes the Cas9 enzyme, guided by RNA, to cut specific genetic locations, thus allowing for the removal, addition, or correction of genes.
It has enormous potential in the treatment of genetic disorders such as sickle cell anemia, cystic fibrosis, and certain cancers. In addition, the focus of research is extended to include applications in agriculture and disease resistance using CRISPR/Cas9. Although promising, ethical issues and off-target effects pose challenges.
TIL Therapy
Tumor-Infiltrating Lymphocyte (TIL) therapy is an advanced immunotherapy that harnesses a patient's own immune cells to fight cancer. TILs, naturally present in tumors, are extracted, expanded in a lab, and reinfused to enhance the body’s immune response.
This therapy shows promise in treating melanoma and other solid tumors. Ongoing research aims to improve its effectiveness, making it a potential breakthrough in personalized cancer treatment.
CD19 Vectors
CD19 vectors are genetic tools used to target CD19, a protein expressed on B cells. These vectors, often lentiviral or AAV-based, deliver genes encoding chimeric antigen receptors (CARs) or other therapeutic constructs.
CD19-targeted CAR T-cell therapies have shown remarkable success in treating B-cell malignancies like leukemia and lymphoma. Additionally, CD19 vectors aid in studying B-cell biology and developing targeted immunotherapies by enabling precise genetic modifications.
CD22 Vectors
CD22 CAR T-cell vectors are engineered to target CD22, a protein expressed on B cells, making them effective in treating relapsed or refractory B-cell malignancies, particularly after CD19-directed therapy failure.
These vectors often incorporate 4-1BB costimulatory and CD3ζ signaling domains for enhanced efficacy and persistence. They show high remission rates but may face challenges like antigen loss or downregulation at relapse. Advances include low-immunogenic constructs and dual-targeting strategies with CD19 for improved outcomes.
BCMA Vectors
BCMA (B-cell maturation antigen) vectors are engineered to target BCMA, a protein highly expressed on malignant plasma cells in multiple myeloma. These vectors, often used in CAR T-cell therapy, enable the modification of T cells to recognize and destroy BCMA-expressing cells.
BCMA-targeted CAR T therapies have shown high response rates in relapsed or refractory multiple myeloma but face challenges like antigen escape and short-lived remissions. Advances include dual-targeting strategies and optimized constructs
CD7 Vectors
CD7 vectors are designed to target CD7, a protein expressed on T cells and natural killer (NK) cells, making them effective for treating T-cell malignancies like T-cell acute lymphoblastic leukemia (T-ALL) and lymphomas.
These vectors often incorporate 4-1BB costimulatory and CD3ζ signaling domains for enhanced efficacy and persistence. They show high remission rates but may face challenges like antigen loss or downregulation at relapse. Advances include low-immunogenic constructs and dual-targeting strategies with CD19 for improved outcomes.
CD33 Vectors
CD33 CAR T cell therapy vectors are genetically engineered viral vectors intended to modify T cells to target the CD33 protein, which is often expressed on acute myeloid leukemia cells.
The vectors introduce a chimeric antigen receptor into T cells, enabling them to recognize and destroy cancer cells expressing the CD33 protein. Stable gene transfer with lentiviral and retroviral vectors has become common in this treatment to ensure effective and durable anti-tumor responses in AML treatment.
BC 11 A Gene
BC11A gene therapy is a new approach to treat sickle cell disease and beta-thalassemia through the reactivation of fetal hemoglobin (HbF) production. In normal circumstances, the BCL11A gene suppresses HbF after birth, but gene therapy approaches, such as CRISPR-Cas9 or lentiviral vectors, silence this gene in red blood cell precursors.
This then allows HbF to compensate for defective adult hemoglobin, reducing disease symptoms. Promising results have been seen in clinical trials, with fewer vaso-occlusive crises in sickle cell disease and reduced transfusion dependence in beta-thalassemia. Targeted gene therapy with BC11A could provide a cure, improving the quality of life for affected individuals.